Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05085444
Recruitment Status : Recruiting
First Posted : October 20, 2021
Last Update Posted : October 20, 2021
Yake Biotechnology Ltd.
Information provided by (Responsible Party):
He Huang, Zhejiang University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : October 8, 2024
Estimated Study Completion Date : October 8, 2024